TrialBlood advances2021

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.

Christian Buske et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.